Elidel and Keloids - a phase IV clinical study of FDA data

Summary:

Keloids is found among people who take Elidel, especially for people who are female, 20-29 old.

The phase IV clinical study analyzes which people take Elidel and have Keloids. It is created by eHealthMe based on reports of 4,352 people who have side effects when taking Elidel from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 11, 2023

4,352 people reported to have side effects when taking Elidel.
Among them, 29 people (0.67%) have Keloids.

What is Elidel?

Elidel has active ingredients of pimecrolimus. It is often used in eczema. eHealthMe is studying from 4,405 Elidel users for its effectiveness, alternative drugs and more.

What is Keloids?

Keloids (overgrown scars left from skin injuries) is found to be associated with 626 drugs and 444 conditions by eHealthMe.

Number of Elidel and Keloids reports submitted per year:

Gender of people who have Keloids when taking Elidel *:

female: 96.43 %
male: 3.57 %

Age of people who have Keloids when taking Elidel *:

Common drugs people take besides Elidel *:

Common side effects people have besides Keloids *:

Weakness: 25 people, 86.21%
Night Sweats (sweating in night): 24 people, 82.76%
Laryngocele (a congenital anomalous air sac communicating with the cavity of the larynx): 20 people, 68.97%
Hodgkin's Lymphoma (cancer originating from white blood cells): 20 people, 68.97%
Hepatomegaly (abnormal enlargement of the liver): 20 people, 68.97%
Hair Loss: 20 people, 68.97%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 20 people, 68.97%
Allergic Rhinitis: 19 people, 65.52%
Rashes (redness): 19 people, 65.52%
Pyelocaliectasis: 18 people, 62.07%

Common conditions people have *:

Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 7 people, 24.14%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 6.90%
Infection: 2 people, 6.90%
Type 2 Diabetes: 1 person, 3.45%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.45%
High Blood Pressure: 1 person, 3.45%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 3.45%
Birth Control: 1 person, 3.45%
Asthma: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Elidel and have Keloids?

Check whether Keloids is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Keloids and when was it recovered:

Keloids in Elidel

Expand to all the drugs that have ingredients of pimecrolimus:

Keloids and drugs with ingredients of pimecrolimus (29 reports)

Alternative drugs to, pros and cons of Elidel:

Elidel (4,405 reports)

Common Elidel side effects:

Browse all side effects of Elidel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Keloids treatments and more:

Keloids (1,005 reports)

COVID vaccines that are related to Keloids:

All the drugs that are associated with Keloids:

Keloids (626 drugs)

All the conditions that are associated with Keloids:

Keloids (444 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pimecrolimus (the active ingredients of Elidel) and Elidel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.